Company Filing History:
Years Active: 2025
Title: Masayo Ohori: Innovator in Humanized Antibody Development
Introduction
Masayo Ohori is a prominent inventor based in Kikuchi, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. Her innovative work focuses on enhancing muscle mass without adversely affecting blood glucose levels.
Latest Patents
Masayo Ohori holds a patent for an anti-IGF-I receptor humanized antibody. This humanized antibody is designed to increase muscle mass through the IGF-I receptor while maintaining stable blood glucose levels. The patent details that the antibody, or its fragments and derivatives, possesses a specific amino acid sequence, including CDR sequences identified as SEQ ID NOs: 1 to 6. It is specifically engineered to bind to the extracellular domain of the IGF-I receptor.
Career Highlights
Masayo Ohori is associated with Teijin Pharma Limited, where she continues to advance her research and development efforts. Her work has garnered attention for its potential applications in therapeutic treatments aimed at muscle growth and metabolic regulation.
Collaborations
Masayo collaborates with notable colleagues, including Akira Tanokura and Hirotsugu Kato, who contribute to her research initiatives and projects.
Conclusion
Masayo Ohori's innovative work in the field of humanized antibodies exemplifies the intersection of biotechnology and health. Her contributions are paving the way for new therapeutic approaches that could significantly impact muscle mass enhancement and metabolic health.